Abstract:Objective To investigate mutation status of isocitrate dehydrogenase (IDH) 1 and IDH2 genes in Chinese patients with gliomas in correlation with clinicopathological characteristics.Methods Formalin-fixed and paraffin-embedded (FFPE) tissue samples of 234 gliomas were collected including the matched blood samples in 30 patients.DNA was extracted,followed by PCR-Sanger sequencing to detect IDH1 and IDH2 gene mutations.Immunohistochemistry was performed using mutation-specific antibody recognizing IDH1R132H mutation.Immunostains for p53 and epidermal growth factor receptor (EGFR) were also performed.Oligodendroglial tumors with IDH mutation were double stained with IDH1R132H and GFAP by immunofluorescence to investigate the location of IDH1 R132H expression.Results (1) By IDH1 heterozygous somatic mutation analysis,Arg132His (c:G395A) was found in 31.6％ (74 of 234) of the cases.IDH mutations were more frequent in oligoastrocytomas (9/13),anaplastic oligoastrocytomas (7/11),oligodendrogliomas (18/26,69.2％),anaplastic oligodendrogliomas (8/10),and less frequent in diffuse astrocytomas (17/47,36.2％),anaplastic astrocytomas (5/18),and glioblastomas (10/69,14.5％).The mutation rate inversely correlated with the tumor grade in a linear fashion in astrocytic tumors (P =0.007).Primary glioblastomas were characterized by a lower frequency of mutations than secondary glioblastomas (5/55 vs.5/14,P =0.036); IDH mutation was not detected in pilocytic astrocytoma and ependymoma.No IDH2 mutation was identified in this study cohort.(2) Immunohistochemistry of IDH1R132H demonstrated a strong cytoplasmic staining in 80 cases,which was highly correlated with IDH mutation status (P =0.001).IDH1R132H was highly specific to tumor cells.(3) p53 immunostain was significantly correlated the IDH mutation in diffuse astrocytoma,anaplastic astrocytoma and secondary glioblastomas (P =0.007,0.026,0.038 respectively).(4) No correlation between EGFR and IDH mutation was found.Conclusions High prevalence of IDH heterozygous somatic mutation occurs in the earlier stage of gliomas,which can be detected by mutation-specific antibody IDH1R132H.Furthermore,evaluation of p53 and EGFR expression combined with IDH mutation analysis may significantly aid in the diagnosis and differential diagnoses of gliomas in Chinese patients.

Possible Role of Isocitrate Dehydrogenase Gene Mutation in the Genesis of Glioma

[Relationship between clinical characteristics and myelodysplastic syndrome patients with isocitrate dehydrogenase gene mutations].

Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma

IDH gene mutation in glioma

IDH1 Mutation and DNA Methylation of Astrocytic Glioma Patients

Correlation of IDH1/2 Mutation with Clinicopathologic Factors and Prognosis in Anaplastic Gliomas: a Report of 203 Patients from China

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas

Idh1/Idh2 Mutations Define The Prognosis And Molecular Profiles Of Patients With Gliomas: A Meta-Analysis

Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients.

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets

IDH-1R132H Mutation Status in Diffuse Glioma Patients: Implications for Classification.

Mutation Analysis Of Idh1 In Paired Gliomas Revealed Idh1 Mutation Was Not Associated With Malignant Progression But Predicted Longer Survival

IDH1 mutations inhibit multiple α-ketoglutarate-dependent dioxygenase activities in astroglioma

Isocitrate Dehydrogenase (IDH)1/2 Mutations As Prognostic Markers in Patients with Glioblastomas

A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer Database

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications

Mutations in IDH1/2 Genes Predict Better Disease Outcome of Glioma Patients-A Study from Western India

Integrated analysis of the genomic and transcriptional profile of gliomas with isocitrate dehydrogenase-1 and tumor protein 53 mutations

Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma

Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α

IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced